MILNACIPRAN HYDROCHLORIDE

N/A

Manufactured by Allergan, Inc.

13,899 FDA adverse event reports analyzed

Last updated: 2026-04-15

About MILNACIPRAN HYDROCHLORIDE

MILNACIPRAN HYDROCHLORIDE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Allergan, Inc.. The most commonly reported adverse reactions for MILNACIPRAN HYDROCHLORIDE include NAUSEA, PAIN, HEADACHE, DRUG INEFFECTIVE, VOMITING. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for MILNACIPRAN HYDROCHLORIDE.

Top Adverse Reactions

NAUSEA686 reports
PAIN504 reports
HEADACHE483 reports
DRUG INEFFECTIVE464 reports
VOMITING348 reports
FATIGUE336 reports
DIZZINESS328 reports
INSOMNIA323 reports
DEPRESSION288 reports
HYPERHIDROSIS286 reports
ANXIETY267 reports
OFF LABEL USE254 reports
DRUG HYPERSENSITIVITY246 reports
BLOOD PRESSURE INCREASED208 reports
MALAISE206 reports
RASH202 reports
ARTHRALGIA200 reports
MIGRAINE197 reports
FEELING ABNORMAL193 reports
DIARRHOEA184 reports
ABDOMINAL PAIN UPPER181 reports
SUICIDAL IDEATION180 reports
DYSPNOEA179 reports
ASTHENIA173 reports
PALPITATIONS167 reports
HEART RATE INCREASED164 reports
PARAESTHESIA160 reports
MEMORY IMPAIRMENT157 reports
FALL153 reports
CONSTIPATION152 reports
HYPERTENSION150 reports
HYPOAESTHESIA149 reports
PRURITUS147 reports
WEIGHT INCREASED143 reports
HOT FLUSH142 reports
FIBROMYALGIA141 reports
PAIN IN EXTREMITY141 reports
TREMOR140 reports
WEIGHT DECREASED136 reports
GASTROOESOPHAGEAL REFLUX DISEASE131 reports
BACK PAIN128 reports
CONDITION AGGRAVATED126 reports
DECREASED APPETITE126 reports
CHEST PAIN122 reports
MUSCLE SPASMS119 reports
CONFUSIONAL STATE108 reports
FLUSHING103 reports
SOMNOLENCE103 reports
VISION BLURRED99 reports
DRUG INTOLERANCE95 reports
DRUG DOSE OMISSION92 reports
PYREXIA92 reports
ABDOMINAL DISCOMFORT89 reports
ALOPECIA88 reports
INJECTION SITE PAIN88 reports
URTICARIA88 reports
DRY MOUTH85 reports
DRUG INTERACTION84 reports
SINUSITIS83 reports
ABDOMINAL PAIN80 reports
GAIT DISTURBANCE80 reports
HYPERSENSITIVITY80 reports
AGITATION79 reports
PRODUCT USE IN UNAPPROVED INDICATION79 reports
IRRITABILITY78 reports
CRYING75 reports
TACHYCARDIA75 reports
CHRONIC KIDNEY DISEASE74 reports
MYALGIA74 reports
RHEUMATOID ARTHRITIS74 reports
BLEPHAROSPASM72 reports
PERIPHERAL SWELLING72 reports
PNEUMONIA72 reports
RENAL FAILURE71 reports
CONTUSION70 reports
EPILEPSY67 reports
NASOPHARYNGITIS66 reports
TASTE DISORDER66 reports
OEDEMA PERIPHERAL65 reports
SWELLING65 reports
CHILLS64 reports
SEROTONIN SYNDROME64 reports
URINARY TRACT INFECTION64 reports
LOSS OF CONSCIOUSNESS63 reports
MUSCULAR WEAKNESS62 reports
ACUTE KIDNEY INJURY60 reports
COUGH60 reports
JOINT SWELLING60 reports
UNEVALUABLE EVENT60 reports
AMNESIA57 reports
DYSURIA57 reports
SLEEP DISORDER57 reports
BALANCE DISORDER56 reports
NECK PAIN56 reports
ERYTHEMA55 reports
PRODUCT QUALITY ISSUE54 reports
ANGER53 reports
INFLUENZA52 reports
OSTEOARTHRITIS52 reports
WITHDRAWAL SYNDROME52 reports

Report Outcomes

Out of 5,920 classified reports for MILNACIPRAN HYDROCHLORIDE:

Serious 42.2%Non-Serious 57.8%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Female5,031 (89.5%)
Male566 (10.1%)
Unknown27 (0.5%)

Reports by Age

Age 43146 reports
Age 55142 reports
Age 58126 reports
Age 56121 reports
Age 54119 reports
Age 50113 reports
Age 51109 reports
Age 46107 reports
Age 57105 reports
Age 60104 reports
Age 61104 reports
Age 53103 reports
Age 59103 reports
Age 49100 reports
Age 6299 reports
Age 5297 reports
Age 4796 reports
Age 4593 reports
Age 4890 reports
Age 6389 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with MILNACIPRAN HYDROCHLORIDE?

This profile reflects 13,899 FDA FAERS reports that mention MILNACIPRAN HYDROCHLORIDE. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for MILNACIPRAN HYDROCHLORIDE?

Frequently reported terms in FAERS include NAUSEA, PAIN, HEADACHE, DRUG INEFFECTIVE, VOMITING, FATIGUE. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures MILNACIPRAN HYDROCHLORIDE?

Labeling and FAERS entries often list Allergan, Inc. in connection with MILNACIPRAN HYDROCHLORIDE. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.